These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9803358)

  • 1. Vascular endothelial growth factor (VEGF) serum levels during cancer immunotherapy with IL-2: preliminary considerations.
    Lissoni P; Fumagalli L; Giani L; Rovelli F; Confalonieri G; Pescia S
    Int J Biol Markers; 1998; 13(2):98-101. PubMed ID: 9803358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in circulating dendritic cells and IL-12 in relation to the angiogenic factor VEGF during IL-2 immunotherapy of metastatic renal cell cancer.
    Bonfanti A; Lissoni P; Bucovec R; Rovelli F; Brivio F; Fumagalli L
    Int J Biol Markers; 2000; 15(2):161-4. PubMed ID: 10883890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of IL-2 preoperative immunotherapy on surgery-induced changes in angiogenic regulation and its prevention of VEGF increase and IL-12 decline.
    Brivio F; Lissoni P; Rovelli F; Nespoli A; Uggeri F; Fumagalli L; Gardani G
    Hepatogastroenterology; 2002; 49(44):385-7. PubMed ID: 11995457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone.
    Lissoni P; Rovelli F; Baiocco N; Tangini G; Fumagalli L
    Anticancer Res; 2001; 21(1B):777-9. PubMed ID: 11299843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy and angiogenesis in advanced cancer: vascular endothelial growth factor (VEGF) decline as predictor of disease control during taxol therapy in metastatic breast cancer.
    Lissoni P; Fugamalli E; Malugani F; Ardizzoia A; Secondino S; Tancini G; Gardani GS
    Int J Biol Markers; 2000; 15(4):308-11. PubMed ID: 11192826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1.
    Lissoni P; Malugani F; Bonfanti A; Bucovec R; Secondino S; Brivio F; Ferrari-Bravo A; Ferrante R; Vigoré L; Rovelli F; Mandalà M; Viviani S; Fumagalli L; Gardani GS
    J Biol Regul Homeost Agents; 2001; 15(2):140-4. PubMed ID: 11501971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-angiogenic activity of melatonin in advanced cancer patients.
    Lissoni P; Rovelli F; Malugani F; Bucovec R; Conti A; Maestroni GJ
    Neuro Endocrinol Lett; 2001; 22(1):45-7. PubMed ID: 11335879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.
    Lissoni P; Bordin V; Vaghi M; Fumagalli L; Bordoni A; Mengo S; Bucovec R; Fumagalli E; Malugani F; Ardizzoia A; Giani L; Gardani GS; Tancini G
    Anticancer Res; 2002; 22(2B):1061-4. PubMed ID: 12168901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
    Braybrooke JP; O'Byrne KJ; Propper DJ; Blann A; Saunders M; Dobbs N; Han C; Woodhull J; Mitchell K; Crew J; Smith K; Stephens R; Ganesan TS; Talbot DC; Harris AL
    Clin Cancer Res; 2000 Dec; 6(12):4697-704. PubMed ID: 11156222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
    Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma.
    Sato K; Tsuchiya N; Sasaki R; Shimoda N; Satoh S; Ogawa O; Kato T
    Jpn J Cancer Res; 1999 Aug; 90(8):874-9. PubMed ID: 10543260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients.
    Salgado R; Vermeulen PB; Benoy I; Weytjens R; Huget P; Van Marck E; Dirix LY
    Br J Cancer; 1999 May; 80(5-6):892-7. PubMed ID: 10360671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients.
    Bachelot T; Ray-Coquard I; Menetrier-Caux C; Rastkha M; Duc A; Blay JY
    Br J Cancer; 2003 Jun; 88(11):1721-6. PubMed ID: 12771987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients.
    Dirix LY; Vermeulen PB; Pawinski A; Prové A; Benoy I; De Pooter C; Martin M; Van Oosterom AT
    Br J Cancer; 1997; 76(2):238-43. PubMed ID: 9231925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between serum levels of interleukin-6 and vascular endothelial growth factor in gastric carcinoma.
    Huang SP; Wu MS; Wang HP; Yang CS; Kuo ML; Lin JT
    J Gastroenterol Hepatol; 2002 Nov; 17(11):1165-9. PubMed ID: 12453275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum angiogenic activity: diagnostic relevance in renal cell carcinoma.
    Beecken WD; Bentas W; Glienke W; Linneweber J; Jonas D; Binder J; Kramer W
    Eur Urol; 2002 Oct; 42(4):364-9. PubMed ID: 12361902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenic factors: vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b-FGF) are not necessarily elevated in patients with advanced renal cell carcinoma.
    Edgren M; Lennernäs B; Larsson A; Kälkner KM
    Anticancer Res; 2001; 21(2B):1423-9. PubMed ID: 11396226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer.
    Feldman AL; Tamarkin L; Paciotti GF; Simpson BW; Linehan WM; Yang JC; Fogler WE; Turner EM; Alexander HR; Libutti SK
    Clin Cancer Res; 2000 Dec; 6(12):4628-34. PubMed ID: 11156212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between plasma levels of vascular endothelial growth factor and serum levels of interleukin-12 in patients with colorectal cancer.
    Nakayama Y; Sako T; Shibao K; Onitsuka K; Nagashima N; Hirata K; Nagata N; Itoh H
    Anticancer Res; 2000; 20(6A):4097-102. PubMed ID: 11131678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of cancer subcutaneous immunotherapy with interleukin-2 in relation to the pretreatment levels of tumor growth factor insulin-like growth factor-1.
    Lissoni P; Barni S; Ardizzoia A; Frigerio F; Paolorossi F; Cazzaniga M; Tancini G; Rocco F; Aapro M
    Tumori; 1995; 81(4):261-4. PubMed ID: 8540123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.